Lifetime intense physical activity may lower risk for non-Hodgkin lymphoma
(American Association for Cancer Research) Performing vigorous physical activity over one's lifetime may lower risk for non-Hodgkin lymphoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2015 Category: Global & Universal Source Type: news

Prostate Cancer Prevention: Ways to Reduce Your Risk
Prostate cancer prevention: Ways to reduce your risk There's no proven prostate cancer prevention strategy. But you may reduce your risk of prostate cancer by making healthy choices, such as exercising and eating a healthy diet. Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma, also called non-Hodgkin lymphoma, is cancer that originates in your lymphatic system, the disease-fighting network [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 1, 2015 Category: Databases & Libraries Source Type: news

Hodgkin’s lymphoma survivors at heightened risk of CVD
Complications may be consequence of radiotherapy and chemotherapy to treat the disease, research suggestsRelated items from OnMedicaProstate cancer medications linked with increased risk of death from pre-existing heart problemsMore intensive chemo boosts survival of lymphoma patients Low dose chemo and radiotherapy halves bladder cancer relapse rateSurvival from non-Hodgkin lymphoma doubles since 1970sWomen smokers have double risk of Hodgkin’s lymphoma (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 28, 2015 Category: UK Health Source Type: news

Changes in cancer epigenome implicated in chemotherapy resistance, lymphoma relapse
Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin's lymphoma. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 20, 2015 Category: Science Source Type: news

Changes in cancer epigenome implicated in chemotherapy resistance and lymphoma relapse
(Weill Cornell Medical College) Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings from Weill Cornell Medical College investigators indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin's lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2015 Category: Cancer & Oncology Source Type: news

14.04.15: Not intended for U.S. and UK Media - Bayer Expands Clinical Development Program for Novel
PI3K Inhibitor Copanlisib in Non-Hodgkin's LymphomaTwo new Phase III trials to be initiated in patients with indolent non-Hodgkin's lymphoma / One new Phase II trial to be initiated in diffuse large B-cell lymphoma mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 15, 2015 Category: Pharmaceuticals Source Type: news

Rare, deadly lymphoma demystified
(Columbia University Medical Center) This is the first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma, a particularly aggressive form of non-Hodgkin's lymphoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 14, 2015 Category: Global & Universal Source Type: news

How Becoming an Active Patient Likely Saved My Husband's Life
When my husband was diagnosed with Stage IV Non-Hodgkin's Lymphoma back in 1999, we were devastated. Like the millions of other people around the world who learn they have cancer every year, we journeyed through the common five stages of grief: denial, anger, bargaining, depression, and acceptance. Sometimes we might go through all five stages in one day. Sometimes we might spend weeks stuck on one stage, feeling completely paralyzed and unable to move forward. And why is it exactly that we grieved and that millions of others grieve annually in the face of a diagnosis? It's simple. When a doctor presents a diagnosis such ...
Source: Healthy Living - The Huffington Post - March 30, 2015 Category: Consumer Health News Source Type: news

Low vitamin D linked to worse prognosis in type of non-Hodgkin lymphoma
(University of Rochester Medical Center) A new study found that people with lower vitamin D levels prior to treatment for follicular lymphoma succumb to the disease or face relapse earlier than patients with sufficient vitamin D levels in their blood. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 30, 2015 Category: Cancer & Oncology Source Type: news

Popular Weed-Killer Is Probably Carcinogenic, WHO Says
LONDON (AP) — One of the world's most popular weed-killers — and the most widely used kind in the U.S. — has been labeled a probable carcinogen by the International Agency for Research on Cancer. The decision was made by IARC, the France-based cancer research arm of the World Health Organization, which considered the status of five insect and weed killers including glyphosate, which is used globally in industrial farming. The U.S. Environmental Protection Agency, which makes its own determinations, said it would consider the French agency's evaluation. The French agency has four levels of risks for pos...
Source: Healthy Living - The Huffington Post - March 21, 2015 Category: Consumer Health News Source Type: news

FDA Expands Imbruvica Use for Non-Hodgkin Lymphoma
Imbruvica (ibrutinib) can now be prescribed for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 4, 2015 Category: Pharmaceuticals Source Type: news

Roche says study of lymphoma drug shows significant benefit
ZURICH (Reuters) - Swiss drugmaker Roche said on Wednesday a late-stage study of its treatment for slow-growing, or indolent, non-Hodgkin's lymphoma showed significant benefit and met its primary endpoint early. (Source: Reuters: Health)
Source: Reuters: Health - February 4, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 29, 2015 Category: American Health Source Type: news

Hampstead and Westminster men's hockey team in naked calendar for charity
Sixteen of the Hampstead and Westminster Hockey Club men's first team took part in the shoot after a former teammate was diagnosed with non-hodgkin's lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - December 30, 2014 Category: Consumer Health News Source Type: news

Entecavir Lowers HBV Reactivation Risk Better Than LamivudineEntecavir Lowers HBV Reactivation Risk Better Than Lamivudine
A new randomized trial has suggested that entecavir is better than lamivudine for preventing HBV reactivation and HBV-related hepatitis in patients with non-Hodgkin lymphoma who are receiving R-CHOP. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Teen who was 'never ill' now battling cancer and needs a life-saving transplant
Emily Clark, 17, from Cwmbran in Wales, is battling non-hodgkin lymphoma for a second time. Specialists say a transplant is her only hope. (Source: the Mail online | Health)
Source: the Mail online | Health - December 15, 2014 Category: Consumer Health News Source Type: news

5 Life Lessons I Learned From Cancer
According to the American Cancer Society, the statistics are startling. Cancer is claiming more and more lives every day. The numbers tell us that over 1.6 million people will have been diagnosed by the end of 2014 -- a diagnosis that can rock the foundation of anyone's world. In November 1999, that's what it felt like for me and my husband when he was diagnosed with stage IV cancer -- Non-Hodgkin's Lymphoma. At one point, we asked the oncologist what we could do to help support the hospital treatments and aid in the fight against cancer. "Nothing," he said. I'm sure it's not too hard to imagine how devastating...
Source: Healthy Living - The Huffington Post - December 13, 2014 Category: Consumer Health News Source Type: news

North Texas Fracking Zone Sees Growing Health Worries
This story was published by The Center for Public Integrity, a nonprofit, nonpartisan investigative news organization in Washington, D.C. DALLAS—Propped up on a hospital bed, Taylor Ishee listened as his mother shared a conviction that choked her up. His rare cancer had a cause, she believes, and it wasn’t genetics. Others in Texas have drawn the same conclusions about their confounding illnesses. Jana DeGrand, who suffered a heart attack and needed both her gallbladder and her appendix removed. Rebecca Williams, fighting off unexplained rashes, sharp headaches and repeated bouts of pneumonia. Maile Bush, who...
Source: Science - The Huffington Post - December 11, 2014 Category: Science Source Type: news

Glyphosate disrupting root systems, destroying soil nutrients and eliminating earthworms
(NaturalNews) More than 100 million pounds of the weedkiller glyphosate is applied annually to crops in the U.S., contributing to cancers such as non-Hodgkin's lymphoma and liver, pancreas and thyroid cancer, among other health complications. One of the main ingredients in Monsanto's... (Source: NaturalNews.com)
Source: NaturalNews.com - December 10, 2014 Category: Consumer Health News Source Type: news

Cornerstone begins Phase I trial of CPI-613 to treat B-cell non-Hodgkin lymphoma
US-based Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead Altered Energy Metabolism Directed (AEMD) drug candidate CPI-613 to treat patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2014 Category: Pharmaceuticals Source Type: news

Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - December 7, 2014 Category: Pharmaceuticals Source Type: news

Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - December 5, 2014 Category: Pharmaceuticals Source Type: news

New Treatment for Non - Hodgkin Lymphoma Approved
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Poteligeo for Rare Types of Non - Hodgkin Lymphoma
Drug approved to treat relapsed or refractory mycosis fungoides and Sézary syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves First Biosimilar to Non - Hodgkin ’ s Lymphoma Drug
Truxima approved to treat adults with CD20 - positive, B - cell non - Hodgkin's lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Nitrite Consumption May Up Risk for Non - Hodgkin Lymphoma
Nitrite intake linked to carcinogenicity leading to NHL, development of diffuse large B cell lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

Rituximab + Chemo Ups Survival in Pediatric B - Cell Non - Hodgkin Lymphoma
Event - free survival significantly longer for children, teens with high - grade, high - risk disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pediatrics, Pharmacy, Journal, Source Type: news

Massive Non-Hodgkin Lymphoma study underway
This study has resulted many published papers and is considered "huge in scale." (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 6, 2014 Category: Science Source Type: news

Hodgkin's vs. non-Hodgkin's lymphoma
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - November 6, 2014 Category: Consumer Health News Source Type: news

Pharmacyclics and Roche to evaluate Imbruvica-Gazyva combination in lymphoma, leukaemia patients
Pharmacyclics and Roche have entered into a clinical drug supply agreement to evaluate the safety, tolerability and preliminary efficacy of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) in patients with non-Hodgkin lymphoma (NHL) an… (Source: Drug Development Technology)
Source: Drug Development Technology - October 17, 2014 Category: Pharmaceuticals Source Type: news

BMS, Pharmacyclics and Janssen partner to evaluate non-Hodgkin's lymphoma drug
Bristol-Myers Squibb (BMS), Pharmacyclics and Janssen Research & Development have collaborated to start a Phase I/II clinical trial to assess the safety, tolerability and preliminary efficacy concerning the combination of OPDIVO (nivolumab) and IMBRU… (Source: Drug Development Technology)
Source: Drug Development Technology - October 14, 2014 Category: Pharmaceuticals Source Type: news

APAC Non-Hodgkin Lymphoma Market to Grow at 6.6% CAGR Through 2020,...
New research report “Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting” elaborated by GBI Research is now...(PRWeb September 26, 2014)Read the full story at http://www.prweb.com/releases/2014/09/prweb12203364.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 27, 2014 Category: Pharmaceuticals Source Type: news

Hodgkin's and Non-Hodgkin's Lymphoma
series:Cancer Treatment and ResearchOver recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic ... (Source: Springer Medicine titles)
Source: Springer Medicine titles - September 23, 2014 Category: Databases & Libraries Tags: Oncology Source Type: news

Cutaneous Intravascular Natural Killer-Cell LymphomaCutaneous Intravascular Natural Killer-Cell Lymphoma
This report documents a case of intravascular lymphoma, a rare and aggressive variant of extranodal non-Hodgkin lymphoma. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020...
ResearchMoz.us include new market research report" Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020" to its huge collection of research reports.(PRWeb September 01, 2014)Read the full story at http://www.prweb.com/releases/2014/09/prweb12135147.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 1, 2014 Category: Pharmaceuticals Source Type: news

B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion...
MarketOptimizer.org adds “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” to its store. Overview of B-cell NHL, including epidemiology, etiology,...(PRWeb September 01, 2014)Read the full story at http://www.prweb.com/releases/2018-non-hodgkins-b-cell/lymphoma-market-analysis/prweb12135505.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 1, 2014 Category: Pharmaceuticals Source Type: news

Kite Pharma's Shares Soar After Study Results
Eight patients with aggressive non-Hodgkin's lymphoma treated with Kite Pharma's cancer drug lead candidate were in complete remission and four others in partial remission, the company said Monday. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 26, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma
(Burns McClellan) Kite Pharma Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor T cell therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2014 Category: Global & Universal Source Type: news

Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
"CD70 is a very promising ADC antigen, which is highly expressed in both NHL and RCC, and has minimal expression in healthy tissues," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics.08/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2014 Category: Cancer & Oncology Source Type: news

Is UK obesity fuelling an increase in 10 cancers?
Conclusion This large UK cohort study of more than 5 million people has found that, although there was variation in the effect of BMI on different cancers, a higher BMI was associated with increased risk of several cancers. Overall, the researchers estimated that a 1kg/m² population-wide increase in BMI would result in 3,790 additional people in the UK each year developing uterus, gallbladder, kidney, cervix, thyroid, leukaemia, liver, colon, ovarian or postmenopausal breast cancer. However, not all of the identified links were completely clear, with some showing a clearer linear association between increasing BMI an...
Source: NHS News Feed - August 14, 2014 Category: Consumer Health News Tags: Obesity Cancer Source Type: news

Seattle Genetics begins Phase I trial of lymphoma and carcinoma drug SGN-CD70A
Seattle Genetics has initiated a Phase I clinical trial assessing SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 13, 2014 Category: Pharmaceuticals Source Type: news

CTI BioPharma receives Israeli approval for aggressive B-cell non-Hodgkin's lymphoma therapy
CTI BioPharma has obtained Israeli Ministry of Health's approval for Pixuvri (pixantrone), as a monotherapy to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma who have received up to three previous c… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 21, 2014 Category: Pharmaceuticals Source Type: news

FDA Approves Beleodaq for Non-Hodgkin Lymphoma
FDA Approves Beleodaq to Treat Rare, Aggressive Form of Non-Hodgkin Lymphoma (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 8, 2014 Category: Journals (General) Source Type: news

Beleodaq OK'd for Rare Form of NHL
WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 3, 2014 Category: Hematology Source Type: news

FDA Approves Belinostat for Rare LymphomaFDA Approves Belinostat for Rare Lymphoma
The new drug is for peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin's lymphoma. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 3, 2014 Category: American Health Source Type: news

Beleodaq Approved for Aggressive non-Hodgkin Lymphoma
When lymph nodes become cancerous (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 3, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Lauryn Robinson loses battle with TWO rare forms of blood cancer
Eight-year-old Lauryn Robinson died at her home in Mold, North Wales, on Sunday, June 29, after a year-long battle with lymphoblastic leukaemia and Burkitts non-Hodgkins lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - July 2, 2014 Category: Consumer Health News Source Type: news

Mayo Clinic Recommends New Routine Testing for some Non-Hodgkin Lymphomas
ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 26, 2014 Category: Databases & Libraries Source Type: news

Combination therapy may help patients with follicular lymphoma
(Rockefeller University Press) Follicular lymphoma is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Researchers show that a high-risk group of patients with the disease could benefit from a novel drug combination. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2014 Category: Cancer & Oncology Source Type: news